AbbVie’s Skyrizi took home the top spot for most pharma brand ad impressions in April 2025, according to data released by ...

Healthcare stocks are generally more resilient in a challenging macro backdrop compared to stocks in other sectors. This is because the need for medicines and medical treatments i ...

AbbVie is strutting into 2025 like it owns the lab, thanks to a performance cocktail of smart acquisitions, clinical wins, ...

AbbVie Inc. (ABBV), headquartered in North Chicago, Illinois, is a biopharmaceutical company discovers, develops, ...

AbbVie stands to benefit from a policy change eliminating the “pill penalty” in Medicare’s drug price negotiations, offering ...

AbbVie snagged yet another spot among April’s highest TV ad spenders, as its Vraylar jumped two spots to eighth place with a ...

IQVIA’s Doug Long offers a lay of the land, including trends and developing issues that are shaping the current market.

AbbVie (NYSE:ABBV) recently secured FDA approval for RINVOQ to treat giant cell arteritis, which alongside a biologics license application for TrenibotE, underscored the company's focus on innovation.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The S&P 500 edged 0.1% higher on Monday, April 28, eking out a fifth straight winning session to kick off a week of key ...

Many rheumatologic conditions such as rheumatoid arthritis and lupus often strike women during their reproductive years, with drugs being the primary therapies. Experts assembled by EULAR determined ...

While AbbVie handily beat expectations this quarter, the company faces declining Humira sales and a challenged aesthetics business, plus the same macro headwinds blowing against the entire industry.